Skip to main content
Premium Trial:

Request an Annual Quote

People in the News

Centogene: Peter Bauer

Peter Bauer has been appointed to the board of management of Centogene, effective Jan. 24., and as managing director of subsidiary Centogene GmbH. He has served as the Centogene's chief medical and genomic officer since 2022 after holding various management positions within the company. Previously, he headed the molecular diagnostics laboratory at the Institute of Medical Genetics and Applied Genomics at University Hospital Tübingen.

Epigenomics: Heino von Prondzynski

Epigenomics said this week that Heino von Prondzynski, chairman of the supervisory board, will resign from his position and the board effective March 31, 2023, for health reasons. Prondzynski was a member of the board from May 2007 to March 2010, and has been chairman since May 2012. Prior to that he served in numerous roles internationally, including as CEO of Roche Diagnostics and a member of Roche's corporate executive committee.

FIND: Ayoade Alakija

FIND has appointed Ayoade Alakija its new chair of the board. Alakija has more than 20 years of experience as a doctor in Asia, the Americas, the Pacific region, Europe, and Africa. She currently is special envoy for the World Health Organization for the Access to COVID-19 Tools Accelerator and is co-chair of the Principals Group. She was previously chief humanitarian coordinator for Nigeria. Also, Soumya Swaminathan and Malebona Precious Matsoso was appointed board members of FIND.

Yourgene Health: Andrew Leeser

Andrew Leeser has been appointed as a non-executive director of Yourgene Health. He is a mid-market corporate transformation specialist and the chairman of the Institute for Turnaround.

Nanomix: Christopher Hetterly

Nanomix has appointed Christopher Hetterly as CFO. He was most recently CFO of Octagos Health, and previously served as CFO of Madrona Ventures. He also has held leadership positions with East West Bank, Palo Alto Capital Group, GE Capital, Diginome DataDNA, and Wells Fargo. Nanomix said Hetterly brings more than 25 years of experience in senior financial roles through which he has raised more than $10 billion in capital for companies including eBay, Netflix, and Symantec.

Exagen: Tina Nova

Exagen has elected Tina Nova as executive chair of its board of directors. Nova succeeds Brian Birk, who served as chair of the board since 2018 and will remain as a board member.

Nova currently serves as president of Veracyte's CLIA business. She was previously president and CEO of Decipher Biosciences until March 2021, when Veracyte acquired Decipher. Nova has also been CEO of Molecular Stethoscope and senior VP and general manager of oncology at Illumina. She was the cofounder, president, and CEO of Genoptix, which was acquired by Novartis in 2011. Nova also serves on the board of Azenta and has been a board member with Veracyte and Arena Pharmaceuticals. She holds a PhD in biochemistry from the University of California, Riverside and a BS in biological sciences from UC Irvine.

Angle: Joseph Eid

Liquid biopsy technology company Angle has appointed Joseph Eid as a non-executive director. Eid is a physician who is board certified in medical oncology, hematology, and internal medicine. He most recently served as chief medical officer and head of global drug development for Luzsana Biotechnology, a subsidiary of Jiangsu Hengrui Pharmaceutical. He has also previously held senior positions in clinical development and medical affairs at Bristol Myers Squibb, Merck, and Hoffman-La Roche.

Centogene: Florian Vogel

Florian Vogel will step down as chief process officer and member of the management board of Centogene, effective Feb. 28. Until 2018, he was the company's senior director of R&D. Centogene did not announce any plans for his replacement.

Prenetics Global: Bayju Thakar

Genomic and diagnostic testing firm Prenetics Global has appointed Bayju Thakar as CEO and a board member of subsidiary Prenetics EMEA, which serves Europe, the Middle East, and Africa. Thakar has more than 20 years of experience in healthcare and digital health, mergers and acquisitions, and strategic partnerships, including as cofounder and CEO of Doctor Care Anywhere, a UK-based telehealth primary care business.

Biological Dynamics: Peter Wulff

Biological Dynamics has appointed Peter Wulff as its CFO, effective Jan. 1. He has more than 35 years of experience in financial management and was most recently CFO at JenaValve Technology. Before that he was the financial corporate officer at Alphatec Spine Holding, Artes Medical, CryoCor, and Pure Biosciences. Based in San Diego, Biological Dynamics' ExoVertita platform isolates extracellular vesicles for multiomic applications.